The firm said that the new instrument, which prepares slides for cytology and aliquot samples for molecular testing, offers workflow benefits to clinical labs.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The firms said that HuaSin obtained exclusive rights to develop a fully automated HPV genotyping assay platform that uses Genomica’s technology.
Roche Diagnostics had sales of CHF 12.88 billion in 2018. For the fourth quarter, diagnostics sales totaled CHF 3.5 billion, up 10 percent year over year.
A molecular assay used in combination with patient-collected samples had similar accuracy to testing with clinician collected samples.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.
The approach could allow doctors to more accurately and more easily identify which patients are free from cancer after radiation treatment.
Called CerMark, the test is aimed at women in resource-constrained settings and will measure proteins linked to HPV infection and cervical disease progression.
The a single-tube, multiplex real-time PCR-based MeltPro High Risk HPV test identifies 14 high-risk genotypes of human papillomavirus and was previously CE marked.